scholarly journals Correction: Stimuli-responsive magnetic nanoparticles for tumor-targeted bimodal imaging and photodynamic/hyperthermia combination therapy

Nanoscale ◽  
2016 ◽  
Vol 8 (25) ◽  
pp. 12843-12843 ◽  
Author(s):  
Kyoung Sub Kim ◽  
Jiyoung Kim ◽  
Joo Young Lee ◽  
Shofu Matsuda ◽  
Sho Hideshima ◽  
...  
Nanoscale ◽  
2016 ◽  
Vol 8 (22) ◽  
pp. 11625-11634 ◽  
Author(s):  
Kyoung Sub Kim ◽  
Jiyoung Kim ◽  
Joo Young Lee ◽  
Shofu Matsuda ◽  
Sho Hideshima ◽  
...  

2015 ◽  
Vol 229 (1-2) ◽  
Author(s):  
Beatriz H. Juarez ◽  
Luis M. Liz-Marzán

AbstractThe integration of different types of materials in a single hybrid system allows the combination of multiple functionalities, which can even be used in conjunction with each other. This strategy has been exploited in nanoscale systems for the creation of so-called smart nanomaterials. Within this category, the combination of inorganic nanoparticles with stimuli-responsive microgels is of very high interest because of the wide variety of potential applications. We present here a short overview of this type of materials in which the nano- and micro-scales get nicely integrated, with a great potential to expand the range of technological applications. We focus mainly on the integration of metal nanoparticles, either by themselves or in combination with semiconductor and magnetic nanoparticles. Various examples of the synergic properties that can be obtained are described, as well as the possibility to extract useful information when optical tweezers are used to manipulate single particles. We expect that this review will stimulate additional research in this field.


2020 ◽  
Vol 8 (35) ◽  
pp. 8022-8036
Author(s):  
Ke Zheng ◽  
Hongyan Liu ◽  
Xinxin Liu ◽  
Libin Jiang ◽  
Linlin Li ◽  
...  

Multidrug combination therapy based on stimuli-responsive liposomes formulated by amphiphilic phthalocyanines has great potential for cancer treatment.


2020 ◽  
Vol 108 ◽  
pp. 110403
Author(s):  
Leilei Guo ◽  
Yurui Xu ◽  
Anwei Zhou ◽  
Lei Zhang ◽  
Lei Sun ◽  
...  

2013 ◽  
Vol 8 (6) ◽  
pp. 709-717 ◽  
Author(s):  
Luís Borlido ◽  
Leila Moura ◽  
Ana M. Azevedo ◽  
Ana C. A. Roque ◽  
Maria R. Aires-Barros ◽  
...  

2005 ◽  
Vol 117 (32) ◽  
pp. 5166-5172 ◽  
Author(s):  
Supratim Giri ◽  
Brian G. Trewyn ◽  
Michael P. Stellmaker ◽  
Victor S.-Y. Lin

Author(s):  
I. V. Zelepukin ◽  
M P. Nikitin ◽  
A. V. Nechaev ◽  
A. V. Zvyagin ◽  
P. I. Nikitin ◽  
...  

2008 ◽  
Vol 136 ◽  
pp. S195
Author(s):  
Joseph Park ◽  
Jaemoon Yang ◽  
Jin-Suck Suh ◽  
Yong-Min Huh ◽  
Seungjoo Haam

Pharmaceutics ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 524
Author(s):  
Shivaprasad Gadag ◽  
Shristi Sinha ◽  
Yogendra Nayak ◽  
Sanjay Garg ◽  
Usha Y. Nayak

Breast cancer has become one of the biggest concerns for oncologists in the past few decades because of its unpredictable etiopathology and nonavailability of personalized translational medicine. The number of women getting affected by breast cancer has increased dramatically, owing to lifestyle and environmental changes. Besides, the development of multidrug resistance has become a challenge in the therapeutic management of breast cancer. Studies reveal that the use of monotherapy is not effective in the management of breast cancer due to high toxicity and the development of resistance. Combination therapies, such as radiation therapy with adjuvant therapy, endocrine therapy with chemotherapy, and targeted therapy with immunotherapy, are found to be effective. Thus, multimodal and combination treatments, along with nanomedicine, have emerged as a promising strategy with minimum side effects and drug resistance. In this review, we emphasize the multimodal approaches and recent advancements in breast cancer treatment modalities, giving importance to the current data on clinical trials. The novel treatment approach by targeted therapy, according to type, such as luminal, HER2 positive, and triple-negative breast cancer, are discussed. Further, passive and active targeting technologies, including nanoparticles, bioconjugate systems, stimuli-responsive, and nucleic acid delivery systems, including siRNA and aptamer, are explained. The recent research exploring the role of nanomedicine in combination therapy and the possible use of artificial intelligence in breast cancer therapy is also discussed herein. The complexity and dynamism of disease changes require the constant upgrading of knowledge, and innovation is essential for future drug development for treating breast cancer.


Sign in / Sign up

Export Citation Format

Share Document